Hoag Participates in Groundbreaking Clinical Trial of Potential Alzheimer’s Vaccine
Among its several clinical trials underway targeting Alzheimer’s disease, Hoag’s Pickup Family Neurosciences Institute is enrolling patients in a revolutionary clinical trial that could lead to a vaccine to helpprevent the disease.
Hoag is the only site in California, and one of only six nationwide, selected to participate in this Phase 1 trial, which is designed to test the safety and tolerability of the vaccine. The study also will assess the vaccine’simpact on beta-amyloid in the brain, one of the biomarkers associated with AD. It’s hoped that eventually the vaccine will help otherwise healthy people who are at risk of developing AD to avoid it altogether.
“Everything about this trial is groundbreaking,” said Gus Alva, M.D., D.F.A.P.A., cognitive neuropsychiatrist and principal investigator of the study at Hoag.
“This effort could lead to a vaccine to prevent a disease that now affects one in eight people over the age of 65.
“After decades of effort,” Dr. Alva added, “the medical field is finally able to offer Alzheimer’s patients hope in the form of promising new drug treatment options, and now a possible prevention, based on whatmay work best for them. We are excited to be at the forefront of such efforts and to make this vaccine trial available to the eligible residents of Orange County.”
For more information about this trial and its selective enrollment criteria, as well as Hoag’s other AD clinical trials, call 949-764- 6797 or email clinicalresearch@hoag.org.